HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. The AUC rose to 92.9% when a personal, symptom-free baseline ECG was available for comparison. According to the company, these results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.
The study, published in JACC: Advances, highlights the potential of HeartBeam's portable technology to aid in the early identification of acute coronary syndromes. HeartBeam's platform technology is designed for portable devices that can collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. This capability allows physicians to identify cardiac health trends and acute conditions outside of medical facilities, redefining cardiac health management. The company holds over 20 issued patents related to its technology enablement.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company's cleared indications for use are available at https://www.heartbeam.com/indications. The results of this study are significant because they demonstrate the potential for a credit card-sized device to help identify heart attack risk, which could lead to earlier intervention and improved patient outcomes. For more information about the press release, visit https://ibn.fm/ainxV.
The study's findings are a step forward in HeartBeam's mission to transform the detection and monitoring of critical cardiac conditions. By providing a portable, cable-free device that can be used wherever the patient is, HeartBeam aims to deliver actionable heart intelligence. The company's technology is designed to enable physicians to direct patients to appropriate care based on cardiac health trends and acute conditions, potentially reducing the time to treatment for heart attacks.
HeartBeam, Inc. is headquartered in the United States and is focused on advancing its clinical program. The company's latest news and updates are available in its newsroom at https://ibn.fm/BEAT. The study published in JACC: Advances represents a key milestone in validating the HeartBeam System's ability to detect heart attacks, and the company plans to pursue further clinical studies to support regulatory submissions for this indication.
